CD274 and neoplasm: Overall, at a 10% significance level, the results did not support the association between the fraction of TCR tumor-associated clone expansion at day 21 from baseline and pre-treatment PD-L1 in immune cells (p = 0.849) or tumor cells (p = 0.3401), although these results should be interpreted with caution since only 18 patients had available PD-L1 staining in this cohort.